Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
What neoadjuvant treatment strategy would you use for an unresectable intrahepatic cholangiocarcinoma with dMMR with the goal of downstaging to achieve surgical resectability?
Patient with ECOG 0-1
Related Questions
What is the data to guide salvage radiation to a patient with recurrence anal cancer to the lymph node after an initial definitive chemoradiation?
How does the management of POLE mutated colorectal cancer differ from that of dMMR/MSI high disease?
For metastatic cholangiocarcinoma that has progressed on first line chemotherapy and immunotherapy, that is HER2 3+, which HER2 regimen is preferred, TDxD, Zanidatamab or tucatinib/trastuzumab?
In a patient with metastatic gastric cancer with high PDL-1 CPS score (10), at what point, if any, would you consider omitting chemotherapy and continuing immunotherapy alone based on CHECKMATE 649 if patient has a favorable or complete response?
Which patients with metastatic HER2 negative, PD-L1 <1% esophageal cancer patients, would you utilize paclitaxel/ramucirumab maintenance?
Would you consider the use of EGFR inhibition (cetuximab/panitumumab) in first line in metastatic right-sided RAS/RAF WT colon cancer, if bevacizumab contraindicated?
What are your top takeaways from ASCO GI 2025?
Which chemotherapy would you recommend for concurrent use with radiation in a patient with localized esophageal adenocarcinoma who has severe Charcot-Marie-Tooth disease?
How would active Crohn's on Adalimumab affect the adjuvant management of a T2aN0M0 gallbladder cancer?
Would you recommend radiation or chemoradiation in a patient with cholangiocarcinoma s/p surgery and adjuvant treatment with single hepatic metastasis 3 years later?